AI-Guided Sarcopenia Risk Assessment and Detection
Israel120 participantsStarted 2026-02-01
Plain-language summary
Sarcopenia, the age-related decline in muscle mass and function, is a major contributor to frailty, disability, and mortality in older adults. Current diagnostic tools assess muscle quantity or function separately and lack predictive biomarkers, limiting early detection and personalized management. This study proposes an AI-driven framework that integrates multimodal physiological, metabolic, and functional data with wearable sensor monitoring to improve sarcopenia risk assessment and guide individualized interventions.
In Phase 1, we will analyze a large retrospective dataset of 3,500 adults to identify early predictors of sarcopenia and develop a machine learning-based risk stratification model. Phase 2 will test a 12-week personalized exercise and nutrition intervention in 120 participants, using real-time sensor data and AI-guided adjustments to optimize outcomes. This integrative approach aims to advance early detection, precision intervention, and long-term muscle health in aging populations.
Who can participate
Age range
50 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Men and women aged 50-70 years
* At risk for sarcopenia based on muscle mass and/or muscle function screening
* Able to participate in supervised exercise training
* Willing to comply with study procedures and provide written informed consent
Exclusion Criteria:
* Participation in structured exercise or weight loss programs within the past 6 months
* Unstable body weight (\>±5%) in the past 6 months
* Current smoking or smoking within the past 6 months
* Pregnancy, breastfeeding, or post-menopause
* Contraindications to MRI (e.g., implanted devices, tattoos, permanent makeup)
* Severe cardiopulmonary disease (e.g., recent myocardial infarction, unstable angina)
* Musculoskeletal or neuromuscular conditions limiting exercise participation
* Cognitive impairment
* Chronic diseases including cancer, diabetes, thyroid disease, hypertension, or chronic renal failure
* Use of medications affecting metabolism
* Secondary liver disease (viral, autoimmune, alcoholic, or drug-induced)
* Alcohol intake \>20 g/day (women) or \>30 g/day (men)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Accuracy of AI-Based Sarcopenia Risk Prediction Model
Timeframe: Baseline to end of follow-up (up to 12 months)